This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

Video highlights from launch of The Daubeny Project

Video highlights from launch of The Daubeny Project

15 Oct 2024

Last month The Oxford Science Park (TOSP) hosted an event to formally launch The Daubeny Project, a 450,000 sq ft development of premium lab space currently under construction at TOSP. The event brought together leaders from the life sciences industry, Oxford’s universities, and key figures from the city’s innovation ecosystem to discuss ways to leverage Oxford’s strengths in collaboration. A key theme was the importance of creating... Read more

Enara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens®

Enara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens®

03 Oct 2024

Enara Bio has raised $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. The round was co-led by new investors, Pfizer Ventures and M Ventures, with participation from all existing investors including RA Capital, Samsara BioCapital and SV Health Investors. The Francis Crick Institute is also joining the round as a new investor. Enara Bio will use the proceeds to advance its pipeline of... Read more

Life science leaders converge at collaboration event hosted by The Oxford Science Park

Life science leaders converge at collaboration event hosted by The Oxford Science Park

30 Sep 2024

Last week The Oxford Science Park (TOSP) hosted an event bringing together leaders from the life sciences industry, Oxford’s universities, and key figures from the city’s innovation ecosystem to discuss ways to leverage Oxford’s strengths in collaboration. Those attending the event, which took place at Magdalen College, heard from the University of Oxford’s Vice-Chancellor, Professor Irene Tracey; Dr Kay Penicud, VP Head of Research... Read more

Theolytics awarded significant £2M Transforming Cancer Therapeutics grant from Innovate UK

Theolytics awarded significant £2M Transforming Cancer Therapeutics grant from Innovate UK

02 Sep 2024

Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic viral therapies, has been awarded £2M from Innovate UK’s prestigious Transforming Cancer Therapeutics grant funding competition to support the clinical development of its lead candidate THEO-260. This non-dilutive funding adds to the £19M raised earlier this year from a strong investor syndicate comprising M Ventures, Taiho Ventures, Epidarex Capital,... Read more

Exscientia and Recursion Enter Definitive Agreement

Exscientia and Recursion Enter Definitive Agreement

13 Aug 2024

Recursion and Exscientia plc have announced the companies have entered into a definitive agreement, combining Recursion, a leading clinical stage technology-enabled biotech company decoding biology to industrialize drug discovery, with Exscientia, a technology-driven clinical stage drug design and development company, committed to creating more effective medicines for patients, faster. Chris Gibson, Co-Founder and CEO of Recursion as well as... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More